Search results for "interferon"

showing 10 items of 963 documents

Prospective study on thyroid autoimmunity and dysfunction related to chronic hepatitis C and interferon therapy.

1997

This study was designed to assess patients with chronic hepatitis C (CHC) for the presence of thyroid autoimmunity and dysfunction, to evaluate the risk of thyroid disorders associated with interferon (IFN) therapy, and to survey the outcome of possible treatment-related thyroid injury. Out of 104 consecutive untreated patients (30 women and 74 men; mean age, 52.7 years), 8 (7.7%) were found seropositive for thyroid autoantibodies (ThyAb), whereas seropositivity in healthy controls was 1/98 (1.3%). The relative increase in risk of developing thyroid autoimmunity associated with CHC was 760% (95% Cl, 220–1300%). No patients had abnormalities of thyroid function tests, but on IFN treatment, 3…

AdultMaleendocrine systemmedicine.medical_specialtyendocrine system diseasesEndocrinology Diabetes and MetabolismThyroid GlandThyrotropinInterferon alpha-2Thyroid function testsGastroenterologyIodide PeroxidaseThyroiditisAutoimmune DiseasesAutoimmune thyroiditisEndocrinologyInternal medicinemedicineHumansProspective StudiesAutoantibodiesAutoimmune diseasemedicine.diagnostic_testbusiness.industryThyroidInterferon-alphaMiddle Agedmedicine.diseaseHepatitis CThyroid DiseasesAnti-thyroid autoantibodiesRecombinant ProteinsDiscontinuationThyroxinemedicine.anatomical_structureImmunologyTriiodothyronineFemaleThyroid functionbusiness
researchProduct

Subcutaneous interferon β-1a may protect against cognitive impairment in patients with relapsing-remitting multiple sclerosis: 5-year follow-up of th…

2013

ObjectiveTo assess the effects of subcutaneous (sc) interferon (IFN) -1a on cognition over 5 years in mildly disabled patients with relapsing-remitting multiple sclerosis (RRMS).MethodsPatients aged 18-50 years with RRMS (Expanded Disability Status Scale score ≤4.0) who had completed the 3-year COGIMUS study underwent standardized magnetic resonance imaging, neurological examination, and neuropsychological testing at years 4 and 5. Predictors of cognitive impairment at year 5 were identified using multivariate analysis.ResultsOf 331 patients who completed the 3-year COGIMUS study, 265 participated in the 2-year extension study, 201 of whom (75.8%; sc IFN β-1a three times weekly: 44 µg, n = …

AdultMalemedicine.medical_specialty5 year follow upMultiple SclerosisAdolescentScienceInjections SubcutaneousBrain damageYoung AdultInterferonRecurrenceInternal medicinemedicineHumansIn patientYoung adultCognitive impairmentSex CharacteristicsMultidisciplinarymedicine.diagnostic_testbusiness.industryMultiple sclerosisQRMultiple Sclerosis Subcutaneous interferon β-1a cognitive impairmentMagnetic resonance imagingInterferon-betamedicine.diseaseTreatment OutcomeImmunologyMedicineFemaleSettore MED/26 - Neurologiamedicine.symptomSafetybusinessCognition DisordersInterferon beta-1amedicine.drugResearch ArticleFollow-Up Studies
researchProduct

Perihepatic lymph nodes and antiviral response in chronic HCV-associated hepatitis.

2003

To identify predictive factors of response to interferon alpha (IFN-alpha) plus ribavirin therapy in patients with chronic hepatitis C (CHC), the presence of lymphadenopathy (LyA) of the hepatoduodenal ligament and other variables were investigated. A total of 110 patients with histologically proven CHC were enrolled in this study. Ultrasound (US) was performed at the start and end of therapy and 6 months after stopping therapy. At baseline, LyA was present in 35 (43.7%) of 80 patients with alanine aminotransferase (ALT) values and grading was significantly higher than in the LyA-negative group. LyA was more frequent in nonresponders (nonR) than in relapsers (relR) or sustained responders (…

AdultMalemedicine.medical_specialtyAcoustics and UltrasonicsEnd of therapyBiophysicsAlpha interferonGastroenterologyAntiviral Agentschemistry.chemical_compoundInternal medicineRibavirinmedicineHumansUltrasound Lymphadenopathy Chronic hepatitis C Treatment Predictive factors.Radiology Nuclear Medicine and imagingProspective StudiesAlanine aminotransferaseLymph nodeLymphatic DiseasesUltrasonographyHepatitisRadiological and Ultrasound Technologybusiness.industryRibavirinInterferon-alphaHepatoduodenal ligamentHepatitis C ChronicMiddle Agedmedicine.diseasePrognosisSurgerymedicine.anatomical_structureLogistic ModelsTreatment OutcomechemistryDrug Therapy CombinationFemaleLymphbusinessUltrasound in medicinebiology
researchProduct

2',5'-Oligoadenylate synthetase activity analysis and human papilloma virus typing as prognostic factors in patients with recurrent respiratory papil…

2004

Objective: Determination of early prognostic factors in patients with recurrent respiratory papillomatosis is extremely important, so the major goal of our prospective, multicentre study was to evaluate (1) the feasibility of various factors to determine prognosis of the clinical course,as well as (2) the response to interferon-alpha therapy in recurrent respiratory papillomatosis. Methods: Forty-two patients with recurrent respiratory papillomatosis were treated with interferon-alpha (3 MU/m2 three times per week; mean therapy duration was 2.7 ± 1.8 years)in 1983–1994 and followed-up until 2003. Human papilloma virus (HPV) type, recurrent respiratory papillomatosis severity and 2′,5′-oligo…

AdultMalemedicine.medical_specialtyAdolescent2'-5'-oligoadenylate synthetase activityAntineoplastic AgentsGastroenterologySeverity of Illness IndexVirusMalignant transformationBasal (phylogenetics)Internal medicinemedicine2'5'-Oligoadenylate SynthetaseHumansTypingProspective StudiesChildPapillomaviridaePapillomabusiness.industryInterferon-alphaGeneral Medicinemedicine.diseasePrognosisRespiratory Tract NeoplasmsTreatment OutcomeOtorhinolaryngologyChild PreschoolImmunologyDNA ViralLeukocytes MononuclearPapillomaFemaleRecurrent Respiratory PapillomatosisNeoplasm Recurrence LocalAirwaybusinessThe Journal of laryngology and otology
researchProduct

Use of Interferon-Alpha in Recurrent Respiratory Papillomatosis: 20-Year Follow-up

2005

Objectives: The aim of this study was analysis of the results of use of interferon-α (IFN-α) in patients with recurrent respiratory papillomatosis (RRP) and correlation of the results with human papillomavirus (HPV) type. Methods: A multicenter prospective series (42 patients from 22 hospitals) yielded 20 years of follow-up of patients with RRP and HPV typing who were treated with IFN-α in doses of 3 MU/m2 3 times per week. Results: During long-term follow-up (mean ± SD, 172 ± 36.8 months), the rate of event-free survival evaluated by Kaplan-Meier analysis was 42.8%, and the overall survival rate was 82.6%. The HPV typing revealed an association of HPV 11 with a more aggressive disease cour…

AdultMalemedicine.medical_specialtyAdolescentAlpha interferonAntineoplastic AgentsInjections IntramuscularDisease-Free Survival03 medical and health sciences0302 clinical medicineInternal medicinemedicineAdjuvant therapyHumansDNA Probes HPVProspective StudiesHuman papillomavirusChild030223 otorhinolaryngologyProspective cohort studyLaryngeal NeoplasmsPapillomaviridaeInterferon alfaPapillomabusiness.industryIncidence (epidemiology)InfantInterferon-alphaGeneral MedicineMiddle AgedSurgeryClinical trialTreatment OutcomeOtorhinolaryngologyChild Preschool030220 oncology & carcinogenesisFemaleNeoplasm Recurrence LocalRecurrent Respiratory PapillomatosisbusinessFollow-Up Studiesmedicine.drugAnnals of Otology, Rhinology & Laryngology
researchProduct

Quality of life in melanoma patients during adjuvant treatment with pegylated interferon-α2b: patients’ and doctors’ views

2011

Treatment of malignant melanoma with IFN-α has been associated with significant side-effects. The aim of this retrospective monocentric non-randomized study was first to evaluate the impact on quality of life (QOL) in 30 melanoma patients treated with once weekly 2 μg/kg PEG-IFN-α2b for 18 months, and second to examine whether there is a difference in patients' and physicians' perception of QOL. Data on QOL were collected by means of the EORTC QLQ-C30 questionnaire completed by the patient before consultation at baseline and every three months during treatment. A second questionnaire was filled out independently by the physician, based on the consultation and patient file. All data were rou…

AdultMalemedicine.medical_specialtyAdolescentEvery Three Monthsmedicine.medical_treatmentOnce weeklyDermatologyInterferon alpha-2Antiviral AgentsPolyethylene GlycolsYoung AdultAmbulatory careQuality of lifePegylated interferonHumansMedicineIn patientMelanomaAgedRetrospective StudiesAged 80 and overbusiness.industryMelanomaInterferon-alphaMiddle Agedmedicine.diseaseRecombinant ProteinshumanitiesChemotherapy AdjuvantQuality of LifePhysical therapyFemalebusinessAdjuvantmedicine.drugEuropean Journal of Dermatology
researchProduct

Individualized treatment with combination of Peg-interferon alpha 2b and ribavirin in patients infected with HCV genotype 3.

2010

The benefit of individualizing treatment for patients with genotype 3 HCV infection on the basis of viral clearance at week 4 (wk4-R) has not been firmly established.Four hundred and fourteen patients received Peg-interferon alpha-2b plus 1000-1200 mg of ribavirin daily according with body weightor75 kg. Patients were randomized to standard 24 weeks (Std24) or to a 12 or 36 weeks variable treatment duration (Var12/36). In the variable treatment arm, patients with or without wk4-R were allocated to either 12 or 36 weeks duration.At treatment week 4, HCV RNA was undetectable in 262 patients (63.3%), 136 in the Std24, and 126 in the Var12/36 group (p=0.41). In patients with wk4-R, end-of-treat…

AdultMalemedicine.medical_specialtyAdolescentGenotypeAlpha (ethology)Alpha interferonHepacivirusInterferon alpha-2GastroenterologyAntiviral AgentsPolyethylene Glycolschemistry.chemical_compoundYoung AdultPharmacotherapyInternal medicineGenotypeRibavirinmedicineHumansIn patientPrecision MedicineAgedHepatologybusiness.industryStomachRibavirinInterferon-alphaHepatitis CHepatitis C ChronicMiddle Agedmedicine.diseaseRecombinant ProteinsSurgerymedicine.anatomical_structurechemistryRNA ViralFemalebusinessJournal of hepatology
researchProduct

Does an 'autoimmune' profile affect the clinical profile of chronic hepatitis C? An Italian multicentre survey.

2004

SUMMARY. Nonorgan-specific autoantibodies (NOSA) are common in patients with chronic hepatitis C virus infection. It is unclear whether serological markers of autoimmunity segregate in a cohort of cases with more severe liver damage. We assessed the relationship between NOSA and demographic, biochemical and histological features in 502 subjects with anti-HCV positive, HCV-RNA positive, HBsAg negative chronic hepatitis consecutively referred to four Italian liver units. Percutaneous liver biopsy was performed in all subjects. A single pathologist scored the biopsies using histology activity index classification. The overall prevalence of positivity for any NOSA was 36.9%. Antinuclear antibod…

AdultMalemedicine.medical_specialtyAnti-nuclear antibodyAdolescentAutoimmunityInterferon alpha-2medicine.disease_causeGastroenterologyAntiviral AgentsAutoimmunitySerologyLiver diseaseVirologyInternal medicinemedicineHumansAdverse effectAgedAutoantibodiesHepatologybiologybusiness.industryAutoantibodyInterferon-alphaHepatitis C ChronicMiddle Agedmedicine.diseaseRecombinant ProteinsInfectious DiseasesItalyAntibodies AntinuclearImmunologyCohortbiology.proteinDrug Therapy CombinationFemaleAntibodybusinessJournal of viral hepatitis
researchProduct

Unchanged plasma levels of dimethylarginines and nitric oxide in chronic hepatitis C.

2008

Previous studies have shown that asymmetric dimethylarginine (ADMA), symmetric dimethylarginine (SDMA) and nitric oxide (NO) play a prominent role in liver dysfunction. The objective of this study was to determine whether plasma levels of ADMA, SDMA and NO are altered in patients with chronic hepatitis C.Plasma levels of ADMA, SDMA and NO (nitrite plus nitrate) were measured in 22 patients with chronic hepatitis C and 24 patients with sustained virologic response after treatment with peginterferon plus ribavirin. Seven healthy volunteers served as controls.Plasma levels of ADMA, SDMA and NO were not significantly different between groups: chronic hepatitis C, ADMA 0.55+/-0.06, SDMA 0.22+/-0…

AdultMalemedicine.medical_specialtyArginineInterferon alpha-2ArginineNitric OxideAntiviral AgentsNitric oxidePolyethylene Glycolschemistry.chemical_compoundInterferonInternal medicineBlood plasmaRibavirinMedicineHumansbusiness.industryRibavirinGastroenterologyCase-control studyInterferon-alphaHepatitis CHepatitis C ChronicMiddle Agedmedicine.diseaseRecombinant ProteinsEndocrinologychemistryCase-Control StudiesFemalebusinessAsymmetric dimethylargininemedicine.drugScandinavian journal of gastroenterology
researchProduct

Transfusion-associated chronic hepatitis C: alpha-n1 interferon for 6 vs. 12 months.

1996

Abstract Aims: To compare the long-term effects of brief and prolonged therapy with alpha-n 1 interferon for transfusion-associated chronic hepatitis C. Methods: One hundred and sixteen subjects (male/female 4868, mean age 46.9 years) were studied. Sixty patients were randomised to brief treatment (group 1: interferon 5 Mu/msq. t.i.w. for 2 months, then 3 Mu/msq. t.i.w. for 4 months), and 56 to prolonged treatment (group 2: interferon 5 Mu/msq. t.i.w. for 2 months, then 3 Mu/msq. t.i.w. for 10 months). All were followed for 12 months after stopping interferon. Results: The early response rate was 47.4% (Group 1 [45%], Group 2 [50%]). No "breakthrough" reactivations were observed. The early …

AdultMalemedicine.medical_specialtyCirrhosisAdolescentmedicine.medical_treatmentHepatitis C virusPopulationAlpha interferonmedicine.disease_causeGastroenterologyAntibodiesDrug Administration ScheduleInterferonInternal medicinemedicineHumanseducationInterferon alfaAgededucation.field_of_studyHepatologybusiness.industryInterferon-alphaTransfusion ReactionImmunotherapyMiddle Agedmedicine.diseaseHepatitis CSurgeryChronic DiseaseFemalebusinessComplicationmedicine.drugJournal of hepatology
researchProduct